Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim and University of Dundee announce research alliance

Boehringer Ingelheim and University of Dundee announce research alliance

15th July 2016

Boehringer Ingelheim has announced a new medical research collaboration with the University of Dundee.

The alliance aims to develop proteolysis targeting chimeric molecules (PROTACs), a therapeutic modality that can degrade proteins playing a central role in disease processes, to create a novel class of medicines.

Their work will leverage the expertise of Dr Alessio Ciulli of the university's school of life sciences, one of the pioneers in the field of PROTACs. Boehringer Ingelheim will contribute its own expertise in drug discovery and clinical development of new therapeutic agents.

PROTACs are expected to have a wide range of potential applications in therapeutic areas such as oncology, immunology and respiratory disease, and could make it easier to target disease mechanisms that have been difficult to reach with existing methods.

Dr Clive Wood, senior corporate vice-president for discovery research at Boehringer Ingelheim, said: "Working closely with the researchers at the University of Dundee … we aim to establish a unique platform that can generate PROTAC-based drug candidates for multiple areas of unmet medical need."

This comes after the firm allied with Lilly earlier this week to launch a study of a new metastatic breast cancer therapy.ADNFCR-8000103-ID-801821845-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.